Skip to content
NeuroTechGuide

Three-year CORE-VNS results show seizure reductions growing over time with LivaNova's VNS Therapy

In 531 people with drug-resistant epilepsy across 16 countries, median seizure frequency fell 76% after three years of vagus nerve stimulation, according to an observational study in Neuromodulation.

In briefNeuromodulationResearch

LivaNova announced on October 23 that the full 36-month results of CORE-VNS have been published in Neuromodulation: Technology at the Neural Interface. The study followed 531 people with drug-resistant epilepsy who received a first vagus nerve stimulation implant at 61 sites in 16 countries; 426 completed three years. Among those with 36-month data, median seizure frequency fell 76% from baseline, 64% had at least half as many seizures, and 16% (64 of 392) were seizure-free. The share of participants with seizure-related hospital stays fell from 27% to 7%. The company reports no new safety concerns.

CORE-VNS is an open-label observational study without a control group, and the figures come from a company release.

Learn more: LivaNova in the Directory

Share:XLinkedInBlueskyEmail

More news